Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T Cell-Mediated Immune Responses to AAV and AAV Vectors
Hildegund C.J. Ertl
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Adeno-associated virus as a delivery vector for gene therapy of human diseases
Jiang-Hui Wang, Dominic J. Gessler, Wei Zhan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 196
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Weiran Shen, Shengjiang Liu, Li Ou
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 90
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Motahareh Arjomandnejad, Ishani Dasgupta, Terence R. Flotte, et al.
BioDrugs (2023) Vol. 37, Iss. 3, pp. 311-329
Open Access | Times Cited: 75
Durability of transgene expression after rAAV gene therapy
Manish Muhuri, David Lévy, Martin Schulz, et al.
Molecular Therapy (2022) Vol. 30, Iss. 4, pp. 1364-1380
Open Access | Times Cited: 66
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Tong‐Yuan Yang, Manuela Braun, Wibke Lembke, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 26, pp. 471-494
Open Access | Times Cited: 50
Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies
Amit Chhabra, George Bashirians, Christos J. Petropoulos, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 3, pp. 101273-101273
Open Access | Times Cited: 13
The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution
Artyom Kachanov, Anastasiya Kostyusheva, Sergey Brezgin, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2112-2193
Closed Access | Times Cited: 12
A two-pass anion exchange chromatography strategy for enrichment of full capsids in manufacturing of adeno-associated viral vectors
Garima Thakur, Sheldon Mink, A García, et al.
Molecular Therapy — Methods & Clinical Development (2025) Vol. 33, Iss. 2, pp. 101441-101441
Open Access | Times Cited: 1
Gene Therapy in Hemophilia: Recent Advances
E. Carlos Rodríguez‐Merchán, Juan A. De Pablo-Moreno, Antonio Liras
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7647-7647
Open Access | Times Cited: 42
Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications
Elvir Bećirović
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 2
Open Access | Times Cited: 29
In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector
Jeong Hyeon Lee, Jeong Pil Han, Dong Woo Song, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 161-172
Open Access | Times Cited: 23
Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery
Eloïse Hudry, Fumiaki Aihara, Emily K. Meseck, et al.
Molecular Therapy (2023) Vol. 31, Iss. 10, pp. 2999-3014
Open Access | Times Cited: 20
The ice age – A review on formulation of Adeno-associated virus therapeutics
Philip Grossen, Irini Skaripa Koukelli, Joost van Haasteren, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2023) Vol. 190, pp. 1-23
Open Access | Times Cited: 19
Adeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry
Edward Large, Mark Silveria, Grant M. Zane, et al.
Viruses (2021) Vol. 13, Iss. 7, pp. 1336-1336
Open Access | Times Cited: 38
Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches
Suyash Prasad, David Dimmock, Benjamin Greenberg, et al.
Human Gene Therapy (2022) Vol. 33, Iss. 23-24, pp. 1228-1245
Open Access | Times Cited: 27
Gene Therapy Approaches for the Treatment of Hemophilia B
Anastasiia B. Soroka, Sofya G. Feoktistova, Olga Mityaeva, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10766-10766
Open Access | Times Cited: 15
Gene therapy for alpha-1 antitrypsin deficiency: an update
Debora Ferreira, Alisha M. Gruntman, Terence R. Flotte
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 3, pp. 283-291
Open Access | Times Cited: 14
Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors
Helena Costa Verdera, Carmen Unzu, Erika Valeri, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 17-18, pp. 836-852
Closed Access | Times Cited: 14
Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene Therapy
Jennifer Lynn Ford, Eleni Karatza, Hardik Mody, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 115, Iss. 6, pp. 1212-1232
Open Access | Times Cited: 6
Nucleic Acid Armor: Fortifying RNA Therapeutics through Delivery and Targeting Innovations for Immunotherapy
Yi Jiang, Bolong Jiang, Zhenru Wang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8888-8888
Open Access | Times Cited: 6
Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice
Miles C. Smith, Lalitha R. Belur, Andrea D. Karlen, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 1, pp. 101201-101201
Open Access | Times Cited: 5
Role of FoxP3+ Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy
Maite Muñoz-Melero, Moanaro Biswas
Human Gene Therapy (2024) Vol. 35, Iss. 13-14, pp. 439-450
Closed Access | Times Cited: 5
Mitigating the Immunogenicity of AAV-Mediated Gene Therapy with an Immunosuppressive Phosphoserine-Containing Zwitterionic Peptide
Zhefan Yuan, Bowen Li, Wenchao Gu, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 44, pp. 20507-20513
Closed Access | Times Cited: 21
Adeno-associated virus vectors and neurotoxicity—lessons from preclinical and human studies
Daniel Stone, Martine Aubert, Keith R. Jerome
Gene Therapy (2023)
Open Access | Times Cited: 10
Liver directed adeno‐associated viral vectors to treat metabolic disease
Marcel Chuecos, William R. Lagor
Journal of Inherited Metabolic Disease (2023) Vol. 47, Iss. 1, pp. 22-40
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top